<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A primary care physician who focuses on treating elderly patients is researching recommendations for primary, secondary, and tertiary prevention. She is particularly interested in recommendations regarding aspirin, as she has several patients who ask her if they should take it. Of the following, which patient should be started on lifelong aspirin as monotherapy for atherosclerotic cardiovascular disease prevention?? A: A 75-year-old male who had a drug-eluting coronary stent placed 3 days ago, B: A 67-year-old female who has diabetes mellitus and atrial fibrillation, C: A 45-year-old female with no health problems, D: An 83-year-old female with a history of a hemorrhagic stroke 1 year ago without residual deficits, E: A 63-year-old male with a history of a transient ischemic attack,  <response>: This question is asking about which patient should be started on lifelong aspirin monotherapy for atherosclerotic cardiovascular disease prevention based on recommendations for primary, secondary, and tertiary prevention. Choice A can be eliminated because a patient who just had a coronary stent placed would be on dual antiplatelet therapy, not aspirin monotherapy. Choice B can be eliminated because a patient with diabetes and atrial fibrillation would likely be on anticoagulation, not aspirin monotherapy. Choice C can be eliminated because a 45-year-old healthy female would not yet meet criteria for primary prevention with aspirin.Choice D can be eliminated because a patient with a recent hemorrhagic stroke would have a contraindication to aspirin due to increased bleeding risk. Choice E matches the recommendations for a patient with a history of a TIA, making the patient a candidate for lifelong aspirin for secondary prevention of atherosclerotic cardiovascular disease.E: A 63-year-old male with a history of a transient ischemic attack 